Should You Test Uric Acid in CKD Stage 3a/b?
Yes, you should measure serum uric acid in patients with CKD stage 3a or 3b, but only if they have symptoms of gout or a history of gout flares—not routinely for asymptomatic hyperuricemia. The most recent KDIGO 2024 guidelines explicitly recommend against using uric acid-lowering agents in asymptomatic hyperuricemia to delay CKD progression 1, which means routine screening in asymptomatic patients lacks therapeutic utility.
When to Measure Uric Acid
Symptomatic Patients (Measure)
- Active gout or history of gout flares: Measure uric acid to guide urate-lowering therapy (ULT) decisions 1
- First gout flare with CKD stage ≥3: The ACR 2020 guidelines conditionally recommend initiating ULT in this specific scenario, making measurement clinically actionable 2
- Recurrent gout (≥2 flares/year): Strong indication for ULT, requiring baseline uric acid measurement 2
- Presence of tophi or radiographic gout damage: These patients need ULT regardless of uric acid level, but measurement helps guide dosing 2
Asymptomatic Patients (Do Not Routinely Measure)
The KDIGO 2024 guidelines explicitly recommend against treating asymptomatic hyperuricemia to prevent CKD progression (Grade 2D) 1. The ACR 2020 guidelines similarly recommend against initiating ULT in asymptomatic hyperuricemia, even in patients with CKD, noting that 24 patients would need treatment for 3 years to prevent a single gout flare 2.
The Evidence Behind This Approach
Why Not Screen Asymptomatic CKD Patients?
The rationale is straightforward: no proven benefit for CKD outcomes. While elevated uric acid correlates with mortality risk in CKD stages 3-5 3, 4, 5, research shows:
- No impact on CKD progression: A Swedish registry study of 2,466 CKD stage 3-5 patients found no association between baseline uric acid and decline in renal function or time to dialysis 6
- Treatment doesn't slow CKD: The KDIGO 2024 recommendation against treating asymptomatic hyperuricemia for CKD progression is based on lack of evidence that lowering uric acid preserves kidney function in asymptomatic patients 1
- Low conversion rate: Only 20% of patients with uric acid >9 mg/dL develop gout within 5 years 2
When Measurement Becomes Actionable
The key distinction is whether the patient has symptomatic gout. Recent 2025 data shows that achieving target uric acid <6 mg/dL in CKD stage 3 patients with gout was associated with reduced progression to severe kidney disease (HR 0.89,95% CI 0.80-0.98) 7. This suggests benefit in the symptomatic population where treatment is already indicated.
Clinical Algorithm
Step 1: Does the patient have any gout symptoms or history?
- Yes → Measure uric acid and consider ULT per ACR guidelines
- No → Proceed to Step 2
Step 2: Are there specific high-risk features?
- History of urolithiasis with first gout flare → Measure uric acid, consider ULT 2
- Uric acid incidentally found >9 mg/dL with first flare → Consider ULT 2
- Otherwise asymptomatic → Do not routinely measure
Step 3: If gout is present, treatment thresholds:
- ≥2 flares/year: Strong recommendation for ULT 2
- 1 flare with CKD stage ≥3: Conditional recommendation for ULT 2
- Tophi or radiographic damage: Strong recommendation for ULT 2
Important Caveats
The Monitoring Gap
A 2025 retrospective study found that only 48.3% of patients on allopurinol had uric acid monitored within 6 months, and CKD stage didn't affect monitoring rates 8. If you measure uric acid and initiate treatment, you must commit to follow-up monitoring—otherwise the initial measurement serves no purpose.
The U-Shaped Mortality Curve
Recent data shows both high and low uric acid levels associate with increased mortality in CKD stages 3-5, with inflection points around 5.2-6.6 mg/dL 4, 5. This J-shaped relationship suggests overtreating to very low levels may be harmful, but this applies to treatment decisions, not screening decisions in asymptomatic patients.
Practical Consideration
Uric acid naturally rises as GFR declines 9, 10. In CKD stage 3, elevated uric acid is expected and does not independently warrant intervention unless gout symptoms develop. The ACR guidelines note that patients with CKD stage ≥3 have higher likelihood of gout progression and limited treatment options for acute flares 2, which strengthens the case for measuring uric acid once gout manifests, but not before.
Bottom line: Measure uric acid in CKD stage 3a/b patients with gout symptoms or history to guide treatment decisions. Do not screen asymptomatic patients, as current evidence does not support treating asymptomatic hyperuricemia to improve kidney outcomes.